Quick Answer
Design Therapeutics, Inc. reported Diluted EPS of $1.22 per share (loss) for fiscal year 2025.
Design Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.22 | -38.6% |
| 2024 | -$0.88 | +26.1% |
| 2023 | -$1.19 | -4.4% |
| 2022 | -$1.14 | -48.1% |
| 2021 | -$0.77 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.30 | -30.4% | +11.8% |
| June 30, 2025 | -$0.34 | -61.9% | -9.7% |
| March 31, 2025 | -$0.31 | -55.0% | -34.8% |
| September 30, 2024 | -$0.23 | +17.9% | -9.5% |
| June 30, 2024 | -$0.21 | +41.7% | -5.0% |
| March 31, 2024 | -$0.20 | +42.9% | +28.6% |
| September 30, 2023 | -$0.28 | +12.5% | +22.2% |
| June 30, 2023 | -$0.36 | -33.3% | -2.9% |
- Design Therapeutics, Inc. showed a decrease of -38.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Design Therapeutics, Inc.’s diluted eps has declined by 58.4% (from $0.77 per share (loss) to $1.22 per share (loss)).
- The most recent figure is from Design Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: